Indivior (NASDAQ:INDV) CAO Woodrow Anderson Purchases 1,500 Shares of Stock

Indivior PLC (NASDAQ:INDV) CAO Woodrow Anderson acquired 1,500 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were bought at an average cost of $35.69 per share, with a total value of $53,535.00. Following the completion of the acquisition, the chief accounting officer owned 27,638 shares in the company, valued at approximately $986,400.22. This represents a 5.74% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Indivior Stock Performance

INDV opened at $35.30 on Friday. The stock has a market capitalization of $4.17 billion, a price-to-earnings ratio of 12.65 and a beta of 0.86. Indivior PLC has a fifty-two week low of $22.22 and a fifty-two week high of $42.81. The company has a fifty day moving average of $39.40 and a 200 day moving average of $36.00.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. The business had revenue of $343.00 million during the quarter. On average, equities research analysts forecast that Indivior PLC will post 3.66 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Craig Hallum reiterated a “buy” rating and issued a $53.00 target price on shares of Indivior in a report on Tuesday, August 4th. Barclays lowered their price target on Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, August 21st. Finally, Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.17.

Institutional Investors Weigh In On Indivior

A number of large investors have recently bought and sold shares of the company. Quarry LP purchased a new position in Indivior during the 3rd quarter worth approximately $26,000. Raymond James Financial Inc. purchased a new stake in shares of Indivior in the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after acquiring an additional 460 shares during the period. Rockefeller Capital Management L.P. boosted its holdings in Indivior by 512.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after purchasing an additional 1,076 shares during the last quarter. Finally, TD Waterhouse Canada Inc. acquired a new stake in Indivior during the 2nd quarter worth about $63,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.